Yan Leyfman/LinkedIn
Apr 14, 2026, 13:09
Yan Leyfman: Rewriting Sickle Cell Disease Biology with CRISPR Technology
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, Medical Correspondent at OncLive, shared on LinkedIn:
”Thank you to Cancer Network for the feature.
Rewriting the Hemoglobin Switch: CRISPR Targeting in Sickle Cell Disease
Gene editing has moved from concept to clinic.
By leveraging CRISPR to reactivate fetal hemoglobin, we’re no longer just managing Sickle Cell Disease – we’re aiming to rewrite its biology.
Targeting regulators like BCL11A is elegant.
Making it durable, scalable, and accessible is the real challenge.
This is where curative intent becomes tangible.
Worth the read if you’re following where ‘hematology and gene therapy’ is heading.”
Stay updated with Hemostasis Today.
-
May 19, 2026, 11:50Nigusu Tesema: What Is Deep Vein Thrombosis and Why Does It Matter After Surgery?
-
May 19, 2026, 11:50Jason Bobay: Highlights Data-Driven DVT Prevention in International Compression Conference
-
May 19, 2026, 11:50Karl Egan: PEDNET Registry Insights Into Inhibitor Development in Severe Haemophilia A
-
May 19, 2026, 11:15Sarah-Anne Nicholas: Excited to Share My First-Author Publication from My PhD Research
-
May 19, 2026, 10:45Jonathan Douxfils: Why Measuring NETosis Remains a Major Challenge in Translational Research
-
May 19, 2026, 10:39Maria Berghs: Rising Demand for Blood Donations in Sickle Cell Care
-
May 19, 2026, 10:27Amer Zeidan: Looking Forward to Sharing New AML Data at ESH 2026
-
May 19, 2026, 09:38Heghine Khachatryan: Why DVT in Elderly Patients Requires Special Attention?
-
May 19, 2026, 08:52Konstantin Stark: Announcing the Launch of Collaborative Research Center 1784 to Advance Thromboinflammation Research